MarketCap
Facebook
X
TelegramQuarterly report 2026-Q2
added 05-15-2026
Citius Pharmaceuticals ROE Ratio 2011-2026 | CTXR
Annual ROE Ratio Citius Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -58.83 | -56.26 | -35.83 | -32.72 | -17.44 | -52.12 | -63.84 | -44.99 | -47.32 | -49.48 | 456.9 | - | - | - | - | -620.0 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 456.9 | -620.0 | -51.83 |
Quarterly ROE Ratio Citius Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -83.32 | -56.62 | -59.79 | -48.04 | -60.3 | -56.83 | -48.67 | -33.76 | -8659.72 | -8658.93 | -8651.8 | -8640.98 | -8665.93 | -48.0 | -42.93 | -46.78 | -35.52 | -31.73 | -28.61 | -52.78 | -78.98 | -88.63 | -117.66 | -104.75 | -108.75 | -116.47 | -105.37 | -101.08 | -97.29 | -84.03 | -78.84 | -77.02 | -70.39 | -73.07 | -69.6 | -71.39 | -59.51 | -61.45 | 27.87 | 42.22 | 356.12 | 507.56 | 712.72 | 735.97 | 510.97 | 385.79 | 304.64 | 223.04 | 347.62 | 556.4 | 447.81 | 429.48 | 263.99 | 98.51 | 99.09 | 99.24 | 161.73 | 224.22 | 230.94 | 110.49 | 110.49 | 9.72 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 735.97 | -8665.93 | -622.24 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-528.29 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-32.54 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.7 | 3.35 % | $ 199 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 31.61 | 2.46 % | $ 2.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
-5.91 | $ 93.75 | 1.62 % | $ 22.7 B | Germany |
 |
AstraZeneca PLC
AZN
|
21.0 | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 53.6 | 3.9 % | $ 4.82 B |  Schweiz |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-380.03 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
30.52 | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 2.68 | 0.94 % | $ 250 M | Israel |
 |
Abcam plc
ABCM
|
-1.17 | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
3750.6 | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-55.98 | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
63.85 | $ 0.81 | 18.2 % | $ 37 M | Israel |
 |
Esperion Therapeutics
ESPR
|
7.51 | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-17.59 | $ 31.59 | 0.94 % | $ 850 M | USA |
 |
Affimed N.V.
AFMD
|
-183.26 | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
-113.75 | $ 21.99 | 0.23 % | $ 285 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-948.23 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-69.02 | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
24.11 | $ 2.69 | -3.71 % | $ 172 M | USA |
 |
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
575.45 | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
2.47 | $ 8.02 | 0.06 % | $ 5.45 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
36.91 | $ 11.78 | 0.26 % | $ 10.1 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43.82 | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
-139.54 | $ 0.9 | 1.4 % | $ 150 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-44.16 | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
-7.58 | $ 14.75 | -0.97 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.31 | -3.88 % | $ 5.45 M | Israel |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |